EpiEP is a medical device company that has developed a novel interventional platform to enable the treatment of certain deadly cardiac arrhythmias. The company's initial product, now being tested in first-in-man trials in Europe, is the EpiAccess™ system, which seeks to enable safe, reliable, minimally invasive access to the pericardium, or outside surface of the heart. Prior to beginning its first-in-man trials, EpiEP completed animal trials at the Mayo Clinic in Rochester, Minn., in early summer 2011.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/01/12 | $1,600,000 |
Connecticut Innovations | undisclosed |
